Methanesulfonamide, N-[6-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-3-yl]-4-hexyn-1-yl]- manufacturers
- O-2050
-
- $3520.00
-
2026-05-11
- CAS:1883545-42-3
- Purity:
- Supply Ability: 10g
|
| | Methanesulfonamide, N-[6-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-3-yl]-4-hexyn-1-yl]- Basic information |
| Product Name: | Methanesulfonamide, N-[6-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-3-yl]-4-hexyn-1-yl]- | | Synonyms: | Methanesulfonamide, N-[6-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-3-yl]-4-hexyn-1-yl]- | | CAS: | 1883545-42-3 | | MF: | C23H31NO4S | | MW: | 417.56 | | EINECS: | | | Product Categories: | | | Mol File: | 1883545-42-3.mol | ![Methanesulfonamide, N-[6-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-3-yl]-4-hexyn-1-yl]- Structure](CAS/20210111/GIF/1883545-42-3.gif) |
| | Methanesulfonamide, N-[6-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-3-yl]-4-hexyn-1-yl]- Chemical Properties |
| Boiling point | 538.2±60.0 °C(Predicted) | | density | 1.173±0.06 g/cm3(Predicted) | | storage temp. | Store at -80°C | | solubility | <41.76mg/ml in ethanol; <41.76mg/ml in DMSO | | pka | 9.45±0.60(Predicted) |
| | Methanesulfonamide, N-[6-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-3-yl]-4-hexyn-1-yl]- Usage And Synthesis |
| Uses | O-2050 is a high affinity cannabinoid CB1 receptor antagonist with a Ki of 2.5 nM. O-2050 inhibits cannabinoid CB2 receptor (Ki=0.2 nM). O-2050 can cause locomotor stimulation in mice[1]. | | Definition | ChEBI: N-[6-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c][1]benzopyran-3-yl]hex-4-ynyl]methanesulfonamide is a 1-benzopyran. | | in vivo | O-2050 (1, 3, 10, 30 mg/kg; ip; pretreatment 30 mins) produces significant and dose-dependent decreases in food intake in mice. O-2050 (10, 30 mg/kg) significantly causes locomotor stimulation[1]. | | IC 50 | CB1: 2.5 nM (Ki); CB2: 0.2 nM (Ki) | | References | [1] Jenny L Wiley, et al. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol. 2011 Jan 25;651(1-3):96-105. DOI:10.1016/j.ejphar.2010.10.085 |
| | Methanesulfonamide, N-[6-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-3-yl]-4-hexyn-1-yl]- Preparation Products And Raw materials |
|